Cancer vaccines are complex and costly products, with a high risk in long-term research, development, and manufacture. Thus, it is necessary to maximize the potential of rapid formulation development. To achieve this goal, the historical methods for formulation development needs to be updated in a rational and systematic way allowing for better cancer vaccine formulations.
In Creative Biolabs, we offer a diversity of approaches involving biophysical characterization of antigens, evaluation of stabilizers, investigation of interactions between antigen and adjuvants, assessment of product contact materials, and stability monitoring both in real-time and accelerated conditions. With the information gained from these studies, there is a great increase in the probability of rapidly developing a safe, effective, and stable cancer vaccine formulation.
There are two main goals of formulation development. One is to improve the immunogenicity of the vaccine and the other is to improve the stability of vaccine components. At Creative Biolabs, we have designed comprehensive services for cancer vaccine formulation optimization, and each of which takes place in multiple phases of development and is complementary to each other. Besides, our teams have rich experience and dedicated equipment to predict and address potential issues in formulation development processes for the supply of high-quality cancer vaccines.
Fig.2 Components of a rational and systematic approach to the development of vaccine formulations. (Morefield, 2011)
As an expert in the vaccine industry, Creative Biolabs can provide access to adjuvants, bespoke adjuvant R&D activities, adjuvant quality control technology, as well as formulation expertise, training, access to GMP adjuvants, so that customers gain optimal benefit from the use of cancer vaccine formulation technology.
For more details regarding the formulation development of cancer vaccines, please don’t hesitate to contact us.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE